Research analysts who have asked questions during TRINITY BIOTECH earnings calls.
Recent press releases and 8-K filings for TRIB.
Trinity Biotech Reports Q3 2025 Financial Results
TRIB
Earnings
Demand Weakening
- Trinity Biotech reported total revenue of $14.3 million for Q3 2025, a decrease from $15.2 million in Q3 2024, with like-for-like revenue at $14.2 million. This quarter saw strong UniGold HIV sales and the resumption of TrinScreen HIV manufacturing and supply in September.
- The company achieved positive Adjusted EBITDA of $0.5 million in Q3 2025, a significant improvement from a negative $1.4 million in Q3 2024, reflecting progress in its Comprehensive Transformation Plan.
- Net loss for Q3 2025 was $5.1 million, compared to $4.8 million in Q3 2024, but basic and diluted loss per ADS improved to $0.28 from $0.46.
- Gross margin increased significantly to 45.2% in Q3 2025 from 35.0% in Q3 2024. Cash generated from operations was $0.3 million in Q3 2025, a positive shift from $3.6 million cash used in operations in Q3 2024, and the company obtained $4.0 million in additional liquidity in October 2025.
Jan 2, 2026, 9:00 PM
Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives
TRIB
Debt Issuance
Convertible Preferred Issuance
New Projects/Investments
- Trinity Biotech plc announced agreements with Perceptive Advisors, securing $5 million in new term-loan proceeds to strengthen liquidity and fund strategic development, including its continuous glucose monitoring solution, CGM+.
- The company extended its Credit Agreement maturity to January 15, 2027, and established an elective equitization capacity of up to $60 million under the term-loan, allowing for potential debt and cash interest cost reductions through conversion into American Depositary Shares (ADSs).
- Equity settlement mechanisms were also agreed upon for a $5 million milestone payment and a $7.5 million contingent obligation, which can be converted into ADSs, potentially reducing cash requirements.
Dec 23, 2025, 1:55 PM
Trinity Biotech Announces Q2 2025 Financial Results
TRIB
Earnings
Demand Weakening
- Trinity Biotech reported revenue of $10.8 million for the quarter ended June 30, 2025, a decrease from $15.8 million for the corresponding period in 2024. This reduction was primarily due to minimized Rapid HIV production and lower sales in Haemoglobin and Autoimmune products.
- The company's net loss for Q2 2025 was $6.0 million, an improvement from a $6.8 million net loss in Q2 2024. Basic and diluted loss per ADS was $0.32 in Q2 2025, compared to $0.71 in Q2 2024.
- Adjusted EBITDA for Q2 2025 was negative $2.1 million, worsening from negative $1.4 million in Q2 2024.
- Gross margin improved to 42.6% in Q2 2025 from 36.2% in Q2 2024, reflecting sales delivered under a revised operating model. The cash balance at the end of Q2 2025 was $1.5 million, down from $5.3 million at the end of Q2 2024.
Dec 23, 2025, 1:30 PM
Trinity Biotech Announces Major HIV Test Order and Q3 2025 Financial Results
TRIB
Revenue Acceleration/Inflection
Guidance Update
CFO Change
- Trinity Biotech received a significant order for 9 million TrinScreen HIV Tests, with fulfillment anticipated during Q4 2025 and Q1 2026.
- Revenues for Q3 2025 increased by 32% to $14.3 million compared to $10.8 million in Q2 2025.
- The company reported positive Adjusted EBITDA of $0.5 million for Q3 2025, a notable improvement from negative $2.1 million in Q2 2025.
- Trinity Biotech expects to achieve strong additional profitability growth and an increase in Adjusted EBITDA in Q1 and Q2 2026 as it executes its Comprehensive Transformation Plan.
- Paul Murphy has been promoted to Interim Chief Financial Officer.
Dec 23, 2025, 12:40 PM
Trinity Biotech Expands Global Rollout of High-Capacity HbA1c Column System
TRIB
Product Launch
Revenue Acceleration/Inflection
- Trinity Biotech plc announced on December 15, 2025, the expanded global rollout of its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyzer, following regulatory clearances in multiple countries.
- The upgraded system is now available in over 10 countries, including the United States, and significantly increases testing throughput by up to four times while minimizing instrument downtime.
- This expansion is anticipated to generate greater recurring revenue opportunities and margin expansion for Trinity Biotech within the global laboratory HbA1c market, which is currently valued at over $2 billion annually and is projected to exceed $3.5 billion by 2030.
Dec 18, 2025, 6:34 PM
Trinity Biotech Secures Regulatory Approval for Offshored Uni-Gold HIV Test Manufacturing
TRIB
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- Trinity Biotech PLC (TRIB) announced on November 18, 2025, that it has secured World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing activities of its market-leading Uni-Gold™ HIV rapid test.
- This regulatory approval enables the company to transition upstream production from its legacy in-house operations to a more cost-effective outsourced model.
- The strategic move is expected to deliver substantial improvements in gross margin, EBITDA, and cashflow generation, accelerating the company's financial performance transformation and driving sustainable profitability.
Nov 21, 2025, 3:02 PM
Trinity Biotech Announces Collaboration to Advance EpiCapture Prostate Cancer Test
TRIB
New Projects/Investments
Product Launch
- Trinity Biotech plc (TRIB) announced a strategic collaboration with a leading bioinformatics company to conduct advanced analysis on clinical trial data for its EpiCapture prostate cancer test.
- The EpiCapture test is a PCR-based epigenetic liquid biopsy designed to monitor the risk of prostate cancer progressing to more aggressive forms.
- This collaboration is a key step towards the regulatory approval and commercialization of the EpiCapture test, expanding Trinity Biotech's portfolio of innovative technologies.
- The test has demonstrated clinical promise, having correctly predicted all high-grade cancers when used with the PSA test in a published study.
Nov 18, 2025, 4:30 PM
Trinity Biotech Regains Nasdaq Compliance
TRIB
Delisting/Listing Issues
- On September 2, 2025, Trinity Biotech PLC announced it has regained compliance with Nasdaq Listing Requirements.
- The company regained compliance with the $1.00 per share minimum bid price requirement.
- Trinity Biotech also met the minimum market value of publicly held shares (MVPHS) requirement of US $15,000,000.
Sep 2, 2025, 6:17 PM
Quarterly earnings call transcripts for TRINITY BIOTECH.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more